Astra outlines its plan to avoid Nasdaq delisting, including possible reverse stock split

Astra outlines its plan to avoid Nasdaq delisting, including possible reverse stock split


A view from onboard the upper stage of rocket LV0009 during the company’s livestream on March 15, 2022.

Astra / NASASpaceflight

Spacecraft engine manufacturer and small rocket builder Astra on Thursday outlined a plan to avoid having its stock delisted from the Nasdaq.

With an exchange-imposed deadline of April 4 drawing near – and Astra’s stock still below the $1 a share level it needs to exceed to remain on the exchange – the company filed a plan earlier this month, seeking an 180-day extension, it said Thursday.

related investing news

Citi upgrades Truist, says investors are wrong to make 'apples and oranges' comparison with SVB

CNBC Pro

If successful, the appeal would give Astra until Oct. 1 to get its shares above $1 for at least 10 consecutive business days.

“Based on our discussions with representatives of Nasdaq, we expect to hear back from Nasdaq regarding the status of our application on or around April 5, 2023, and we are not aware of any reason why our application would not be approved,” Astra CFO Axel Martinez wrote in a blog post.

Sign up here to receive weekly editions of CNBC’s Investing in Space newsletter.

In its plan, Astra also noted the possibility of conducting a reverse stock split to get back into compliance with Nasdaq’s listing standards. A reverse split does not affect the fundamentals of a company, as it is not dilutive to the stock and does not change the company’s valuation, but it would lift the stock price by combining shares.

A reverse split can be seen as a sign a company is in distress and is trying to “artificially” boost its stock price, or it can be viewed as a way for a viable company with a beaten up stock to continue operations on a public exchange. Functionally, a reverse split, often done as a 1-for-10, would mean a $3 stock, for example, would become $30 a share.

“Astra continues to actively monitor our listing status and intends to preserve our Nasdaq listing,” Martinez wrote.

The company is expected to report fourth-quarter results after market close on Mar. 30.

— CNBC’s Scott Schnipper contributed to this report.



Source

Real estate could be the big winner in the private credit exodus
Business

Real estate could be the big winner in the private credit exodus

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. Barely […]

Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Business

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.  The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]

Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More